 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of [0m
[34mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of [0m
[32mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LORAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: precautions: PRECAUTIONS In patients with depression, a possibility for suicide should be borne in mind; benzodiazepines should not be used in such patients without adequate [0m
[31mantidepressant therapy. Lorazepam should be used with caution in patients with compromised respiratory function [0m[1;31m([0m[31me.g., COPD, sleep apnea syndrome[0m[1;31m)[0m[31m. Elderly or debilitated patients may be more [0m
[31msusceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage [0m
[31mshould not exceed [0m[1;31m2[0m[31m mg. Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use[0m
[31mof the drug should be discontinued. The usual precautions for treating patients with impaired renal or hepatic function should be observed. LORAZEPAM: precautions: As with all benzodiazepines, the use[0m
[31mof lorazepam may worsen hepatic encephalopathy; therefore, lorazepam should be used with caution in patients with severe hepatic insufficiency and/or encephalopathy. Dosage for patients with severe [0m
[31mhepatic insufficiency should be adjusted carefully according to patient response; lower doses may be sufficient in such patients. In patients where gastrointestinal or cardiovascular disorders coexist[0m
[31mwith anxiety, it should be noted that lorazepam has not been shown to be of significant benefit in treating the gastrointestinal or cardiovascular component. Esophageal dilation occurred in rats [0m
[31mtreated with lorazepam for more than [0m[1;31m1[0m[31m year at [0m[1;31m6[0m[31m mg/kg/day. The no-effect dose was [0m[1;31m1.25[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m6[0m[31m times the maximum human therapeutic dose of [0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m. The effect was reversible [0m
[31monly when the treatment was withdrawn within [0m[1;31m2[0m[31m months of first observation of the phenomenon. The clinical significance of this is unknown. LORAZEPAM: precautions: However, use of lorazepam for [0m
[31mprolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper GI disease. Safety and effectiveness of lorazepam in children of less than [0m
[1;31m12[0m[31m years have not been established. Information for Patients Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31m Medication Guide [0m[1;31m)[0m[31m. Risks from Concomitant Use with Opioids Advise both [0m
[31mpatients and caregivers about the risks of potentially fatal respiratory depression and sedation when lorazepam is used with opioids and not to use such drugs concomitantly unless supervised by a [0m
[31mhealthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [0m[1;31m([0m[31msee WARNINGS: Risks from Concomitant Use of [0m
[31mOpioids and PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Abuse, Misuse, and Addiction Inform patients that the use of lorazepam even at recommended doses, exposes users to risks of abuse,[0m
[31mmisuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications [0m[1;31m([0m[31me.g., opioid analgesics[0m[1;31m)[0m[31m, alcohol, and/or illicit substances. Inform patients [0m
[31mabout the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug [0m[1;31m([0m[31msee WARNINGS: [0m
[31mAbuse Misuse, and Addiction and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. Withdrawal Reactions Inform patients that the continued use of lorazepam may lead to clinically significant physical dependence and that [0m
[31mabrupt discontinuation or rapid dosage reduction of lorazepam may precipitate acute withdrawal reactions, which can be life-threatening. LORAZEPAM: precautions: Inform patients that in some cases, [0m
[31mpatients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months. Instruct patients that discontinuation or dosage [0m
[31mreduction of lorazepam may require a slow taper [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. Pregnancy Advise pregnant females that use of lorazepam late in [0m
[31mpregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, lethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding [0m
[31mdifficulties[0m[1;31m)[0m[31m in newborns [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. Instruct patients to inform their healthcare provider if they are pregnant.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: pregnancy: Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the[0m
[31mmajority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not [0m
[31mconfirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, [0m
[31mmalrotated limbs, gastroschisis, malformed skull, and microphthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the [0m
[31mconcurrent control group, they have been reported to occur randomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits [0m
[31mwhich was not seen at lower doses. LORAZEPAM: precautions: Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants[0m
[31mexposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmotherâ€™s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to [0m
[31mlorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects[0m
[31maged [0m[1;31m65[0m[31m and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have [0m
[31ma significant effect on lorazepam kinetics [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal [0m
[31mimpairment, should be considered. Greater sensitivity [0m[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower [0m
[31mdoses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: package_ndc         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: product_ndc         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS â€¢ Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. â€¢ The use of benzodiazepines, [0m
[31mincluding lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. LORAZEPAM: boxed_warning: Before prescribing lorazepam and throughout [0m
[31mtreatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. â€¢ The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical [0m
[31mdependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may [0m
[31mprecipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage [0m[1;31m([0m[31m DOSAGE AND [0m
[31mADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_medguide: â€¢ Store lorazepam tablets in a tightly closed container at room temperature between [0m[1;31m20[0m[31mÂ° to [0m[1;31m25[0m[31mÂ°C [0m[1;31m([0m[1;31m68[0m[31mÂ° to [0m[1;31m77[0m[31mÂ°F[0m[1;31m)[0m[31m. â€¢ Keep lorazepam tablets and all medicines out of the [0m
[31mreach of children. General information about the safe and effective use of lorazepam tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use [0m
[31mlorazepam tablets for a condition for which it was not prescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your [0m
[31mpharmacist or healthcare provider for information about lorazepam tablets that is written for health professionals. What are the ingredients in lorazepam tablets? Active ingredient: lorazepam Inactive[0m
[31mingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. LORAZEPAM: spl_medguide: Distributed by: Aurobindo Pharma USA, Inc. [0m[1;31m279[0m[31m Princeton-Hightstown [0m
[31mRoad East Windsor, NJ [0m[1;31m08520[0m[31m Manufactured by: Aurobindo Pharma Limited Hyderabad-[0m[1;31m500[0m[31m [0m[1;31m032[0m[31m, India For more information, call Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m. This Medication Guide has been [0m
[31mapproved by the U.S. Food and Drug Administration. Repackaged by Preferred Pharmaceuticals, Inc. LORAZEPAM: spl_medguide: Revised: [0m[1;31m06[0m[31m/[0m[1;31m2023[0m[31m         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LORAZEPAM label does not directly address the risk of gastrointestinal ulcer hospitalization. However, it is noted that in patients where gastrointestinal [0m
[32mdisorders coexist with anxiety, lorazepam has not been shown to be of significant benefit in treating the gastrointestinal component. Additionally, there should be frequent monitoring for symptoms of [0m
[32mupper GI disease when lorazepam is used for prolonged periods and in geriatric patients.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: In patients where gastrointestinal[0m[32m...[0m[32m for symptoms of upper GI disease.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the [0m
[34mLORAZEPAM label does not directly address the risk of gastrointestinal ulcer hospitalization. However, it is noted that in patients where gastrointestinal disorders coexist with anxiety, lorazepam has[0m
[34mnot been shown to be of significant benefit in treating the gastrointestinal component. Additionally, there should be frequent monitoring for symptoms of upper GI disease when lorazepam is used for [0m
[34mprolonged periods and in geriatric patients.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: In patients where gastrointestinal[0m[34m...[0m[34m for symptoms of upper GI disease.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the LORAZEPAM label does not directly address the risk of gastrointestinal ulcer hospitalization. However, it is noted that lorazepam has not been shown to be of [0m
[32msignificant benefit in treating the gastrointestinal component in patients where gastrointestinal disorders coexist with anxiety. There is also a recommendation for frequent monitoring for symptoms of[0m
[32mupper GI disease when lorazepam is used for prolonged periods and in geriatric patients."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the LORAZEPAM label does not directly address the risk of gastrointestinal ulcer hospitalization. However, it is noted that lorazepam has not been shown to be of [0m
[34msignificant benefit in treating the gastrointestinal component in patients where gastrointestinal disorders coexist with anxiety. There is also a recommendation for frequent monitoring for symptoms of[0m
[34mupper GI disease when lorazepam is used for prolonged periods and in geriatric patients."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LORAZEPAM increases or decreases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the LORAZEPAM label does not directly address the risk of gastrointestinal ulcer hospitalization. However, it is noted that lorazepam has not been shown to be of [0m
[31msignificant benefit in treating the gastrointestinal component in patients where gastrointestinal disorders coexist with anxiety. There is also a recommendation for frequent monitoring for symptoms of[0m
[31mupper GI disease when lorazepam is used for prolonged periods and in geriatric patients.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for LORAZEPAM does not directly address the risk of gastrointestinal ulcer hospitalization. While it is noted that lorazepam has not been shown to be of significant benefit in treating [0m
[32mthe gastrointestinal component in patients where gastrointestinal disorders coexist with anxiety, and there is a recommendation for frequent monitoring for symptoms of upper GI disease when lorazepam [0m
[32mis used for prolonged periods and in geriatric patients, this does not provide a clear indication of whether LORAZEPAM increases or decreases the risk of gastrointestinal ulcer hospitalization. [0m
[32mTherefore, based on the available FDA label data, we cannot determine the effect of LORAZEPAM on the risk of gastrointestinal ulcer hospitalization.[0m
